Tiglutik
E561111
Tiglutik is an oral suspension formulation of the ALS medication riluzole, designed to help slow disease progression in patients with amyotrophic lateral sclerosis.
Statements (28)
| Predicate | Object |
|---|---|
| instanceOf |
oral suspension
ⓘ
pharmaceutical drug ⓘ |
| activeIngredient | riluzole ⓘ |
| containsDosageForm | oral liquid ⓘ |
| containsSubstance | riluzole ⓘ |
| dosageForm | oral suspension ⓘ |
| drugClass | glutamate release inhibitor ⓘ |
| formulationType | ready-to-use suspension ⓘ |
| hasAdministrationAdvantage | facilitates dosing in patients with swallowing difficulties ⓘ |
| hasTradeName | Tiglutik NERFINISHED ⓘ |
| indication |
ALS
NERFINISHED
ⓘ
amyotrophic lateral sclerosis ⓘ |
| indicationDetail | treatment of patients with amyotrophic lateral sclerosis to extend survival or time to tracheostomy ⓘ |
| intendedUse | management of ALS ⓘ |
| isFormulationOf | riluzole NERFINISHED ⓘ |
| mechanismOfAction |
inactivates voltage-dependent sodium channels
ⓘ
inhibits glutamate release ⓘ interferes with intracellular events following excitatory amino acid receptor activation ⓘ |
| pharmacologicalClass | neuroprotective agent ⓘ |
| regulatoryStatus | prescription only ⓘ |
| routeOfAdministration | oral ⓘ |
| targetPopulation | adult patients with ALS ⓘ |
| therapeuticArea |
neurodegenerative diseases
ⓘ
neurology ⓘ |
| therapeuticEffect | slows disease progression in ALS ⓘ |
| treatmentGoal |
prolong survival in ALS patients
ⓘ
slow progression of ALS ⓘ |
| treatsSymptom | functional decline in ALS ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Riluzole